Related Research Articles
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 52 National Cancer Institute–designated Comprehensive Cancer Centers. It had already been renamed and relocated, to its present site, when the Sloan-Kettering Institute for Cancer Research was founded in 1945, and built adjacent to the hospital. The two medical entities formally coordinated their operations in 1960, and formally merged as a single entity in 1980. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
William S. Breitbart, FAPM, is an American psychiatrist in Psychosomatic Medicine, Psycho-oncology, and Palliative Care. He is the Jimmie C Holland Chair in Psychiatric Oncology, and the Chief of the Psychiatry Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, He is a Professor of Clinical Psychiatry at Weill Medical College of Cornell University. He was president of the Academy of Psychosomatic Medicine, and the Editor-in-Chief of Palliative and Supportive Care.
Fighting Chance is a United States patient advocate organization that provides counseling for cancer patients and caregivers. Independent from any hospital and funded solely by charitable contributions, Fighting Chance, a 501(c)(3) non-profit, provides free access to hard-to-find resources and professional counseling from the time of diagnosis through treatment to survivorship. Headquartered in Sag Harbor, New York, the organization operates on the East End of Long Island and also offers e-counseling outside the area.
Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.
Clinical Trials, subtitled as Journal of the Society for Clinical Trials, is a peer-reviewed academic journal covering clinical trials and related subjects in the field of medical research methodology. It is published six times a year by SAGE Publications on behalf of The Society for Clinical Trials (SCT). The journal's main editor is Colin Begg.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Thomas J. Kelly is an American cancer researcher whose work focuses on the molecular mechanisms of DNA replication. Kelly is director of the Sloan-Kettering Institute, the basic research arm of the Memorial Sloan-Kettering Cancer Center. He holds the Center's Benno C. Schmidt Chair of Cancer Research.
Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Peter B. Bach is a physician and writer at Memorial Sloan-Kettering Cancer Center where he is Director of the Center for Health Policy and Outcomes. His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.
Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College, and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.
Paul Alan Marks was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center.
Cycle for Survival is a nationwide (US) movement to beat rare cancers, owned and operated by Memorial Sloan Kettering Cancer Center (MSK). Since its inception in 2007, Cycle for Survival—with support from its founding partner Equinox Fitness—has raised more than $208 million as of 2019. Cycle for Survival directly allocates 100% of all donations to rare cancer research led by MSK within six months of the events.
Andrew Julian Vickers is a biostatistician and attending research methodologist at Memorial Sloan Kettering Cancer Center. Since 2013, he has also been professor of public health at Weill Cornell Medical College. He is the statistical editor for the peer-reviewed journal European Urology.
Jimmie Coker Holland was a founder of the field of psycho-oncology. In 1977, she worked with two colleagues to establish a full-time psychiatric service at Memorial Sloan Kettering Cancer Center. The program was one of the first of its kind in cancer treatment, and trained its psychologists to specialize in issues specific to people with cancer.
Ann Graham Zauber is an epidemiologist and biostatistician at the Memorial Sloan Kettering Cancer Center, primarily interested in colorectal cancer. Her research has demonstrated the effectiveness of colonoscopy and polyp removal at reducing the incidence of this kind of cancer.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
References
- ↑ "Colin Begg". Memorial Sloan Kettering Cancer Center. Retrieved 2018-12-07.
- ↑ "Clinical Trials". SAGE Journals. Retrieved 2018-12-07.
- ↑ "Breast cancer genes don't have to mean cancer". New Scientist. 2008-01-09. Retrieved 2018-12-07.
- ↑ Alpert, Bill (2002-10-21). "Scary Statistics". Barron's. Retrieved 2018-12-07.
- ↑ "Racial Gap in Cancer Survival Is Not Biological, Study Finds". The New York Times. Reuters. 2002-04-24. ISSN 0362-4331 . Retrieved 2018-12-07.
- ↑ "ASA Fellows list". American Statistical Association. Retrieved 2021-11-03.
| International | |
|---|---|
| Academics | |
